Merit Medical Systems (NASDAQ:MMSI) Given New $92.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo raised its price target for Merit Medical Systems from $83 to $92 while maintaining an “equal weight” rating, implying 6.54% potential upside. Analysts overall rate the stock “Moderate Buy,” with an average target of $104.18.
• Merit Medical reported a quarterly earnings beat, posting $1.12 in EPS versus the $1.04 consensus and $416.24 million in revenue versus $410.56 million expected. Revenue increased 8.4% year over year.
• Shares fell $7.04 to $86.36 in Friday trading, while institutional investors continued to hold nearly all outstanding shares, with ownership reaching 99.66%.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) had its price objective boosted by Wells Fargo & Company from $83.00 to $92.00 in a research report issued on Friday, Benzinga reports. The firm presently has an "equal weight" rating on the medical instruments supplier's stock. Wells Fargo & Company's price objective points to a potential upside of 6.54% from the company's previous close.

A number of other analysts have also commented on the company. Robert W. Baird set a $98.00 price objective on Merit Medical Systems in a research report on Friday, July 31st. Bank of America lifted their price target on shares of Merit Medical Systems from $92.00 to $97.00 and gave the stock a "neutral" rating in a research report on Thursday, August 13th. Zacks Research lowered shares of Merit Medical Systems from a "strong-buy" rating to a "hold" rating in a report on Monday, October 19th. Freedom Capital initiated coverage on shares of Merit Medical Systems in a research report on Tuesday. They set a "hold" rating for the company. Finally, Raymond James Financial restated an "outperform" rating and issued a $100.00 price target on shares of Merit Medical Systems in a research report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Merit Medical Systems presently has an average rating of "Moderate Buy" and an average price target of $104.18.

Merit Medical Systems Stock Performance

Shares of NASDAQ MMSI traded down $7.04 during trading hours on Friday, reaching $86.36. The stock had a trading volume of 723,826 shares, compared to its average volume of 787,708. The company has a market cap of $5.16 billion, a price-to-earnings ratio of 35.70, a PEG ratio of 2.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.20 and a quick ratio of 2.79. The business's fifty day moving average is $88.68 and its two-hundred day moving average is $77.12. Merit Medical Systems has a twelve month low of $59.74 and a twelve month high of $94.85.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its earnings results on Thursday, October 29th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the consensus estimate of $1.04 by $0.08. The company had revenue of $416.24 million for the quarter, compared to the consensus estimate of $410.56 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The firm's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.92 EPS. As a group, research analysts expect that Merit Medical Systems will post 3.84 EPS for the current year.

Institutional Trading of Merit Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of MMSI. Congress Asset Management Co. lifted its stake in shares of Merit Medical Systems by 6.4% during the 3rd quarter. Congress Asset Management Co. now owns 1,260,675 shares of the medical instruments supplier's stock worth $108,708,000 after buying an additional 76,338 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Merit Medical Systems by 1.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier's stock valued at $85,287,000 after purchasing an additional 12,285 shares during the last quarter. William Blair Investment Management LLC bought a new position in shares of Merit Medical Systems during the second quarter worth approximately $78,894,000. Maverick Capital Ltd. lifted its holdings in Merit Medical Systems by 46.9% during the 1st quarter. Maverick Capital Ltd. now owns 714,081 shares of the medical instruments supplier's stock worth $49,222,000 after purchasing an additional 227,915 shares during the last quarter. Finally, Irenic Capital Management LP bought a new stake in Merit Medical Systems in the 2nd quarter valued at $37,623,000. Institutional investors and hedge funds own 99.66% of the company's stock.

More Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Third-quarter results exceeded expectations. Revenue increased 8.4% year over year to $416.2 million, surpassing the $410.6 million consensus estimate. Adjusted EPS was $1.12 versus expectations of $1.04 and $0.92 a year earlier. GAAP EPS rose 51% to $0.70, while GAAP and adjusted operating margins also improved. Merit Medical Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised full-year 2026 earnings guidance. The outlook increase indicates confidence in continued profitability and follows 9% organic constant-currency revenue growth in the quarter. Year-to-date operating cash flow was $175.2 million and free cash flow was $129.5 million, supporting financial flexibility. Merit Medical Raises 2026 Earnings Guidance
• Positive Sentiment: Analysts increased their price targets. BTIG Research raised its target from $105 to $110 and assigned a Buy rating, while other analysts reportedly lifted targets to $106 and $110. These revisions suggest the earnings beat and improved outlook could support additional upside. Analysts Boost Forecasts After Strong Q3 Results
• Positive Sentiment: Merit expanded its cardiac therapies business. The acquisition of Solo Pace adds temporary pacing technology used in transcatheter aortic valve replacement procedures, potentially broadening the company’s cardiac product portfolio. Financial terms were not disclosed. Merit Medical Acquires Solo Pace
• Neutral Sentiment: Coverage is mixed. Freedom Capital initiated coverage with a Hold rating, contrasting with BTIG’s Buy recommendation. At roughly 36 times earnings, MMSI’s valuation leaves less room for execution or guidance disappointments.
• Negative Sentiment: The sales outlook was narrowed. Although earnings guidance increased, analysts noted that Merit narrowed its full-year revenue outlook. That may have tempered enthusiasm and contributed to pressure on the shares despite the quarterly beat. Merit Medical Lifted Guidance

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.

The company's product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.

Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.